You want to join a clinical trial. Here’s what to know about the hurdles.

The Gap Between Wanting a Trial and Actually Getting One

Activelifezero.com – More than seven in ten adults living with a chronic illness say they would step into a clinical trial if the door were opened for them. Yet the reality of how most patients encounter the research pipeline tells a very different story. A recent online survey covering over 2,000 adults revealed that roughly two-thirds of respondents had never once been asked by their own doctor whether a trial might suit their condition. A separate analysis drawing on 2020 data found that only about 9 percent of adults had ever received an invitation to take part in one. The disconnect between expressed willingness and actual enrollment is not a minor administrative glitch; it is a structural failure that shapes what medicines reach shelves and what therapies remain locked in the lab.

Why Trials Struggle to Fill Seats

Even when a patient and a study appear to be a natural match, a cascade of practical obstacles can derail enrollment. Geographic distance from a qualifying site, the cost of travel and lodging, lost wages during visit days, and the sheer time commitment of repeated appointments all conspire to keep would-be volunteers on the outside. The consequences are measurable: by one widely cited estimate, as many as 86 percent of trials fail to hit their recruitment goals within the planned study window. Unfilled slots delay data collection, stretch timelines, and can ultimately postpone or derail approval of treatments that thousands of patients are waiting for.

The problem does not end at the front door. Alan Balch, executive board chair of the Patient Advocate Foundation — an organization that maintains a clinical-trial search tool and a library of patient-education materials — frames the issue in blunt terms:

“Recruitment is one thing — retention is another. Every touchpoint is an opportunity for access and affordability to be a problem.”

Each follow-up visit, each imaging scan, each blood draw represents another moment where a participant must weigh the cost of showing up against the cost of missing work or arranging childcare. Drop-off rates erode the statistical power of a study and waste the resources already invested.

What Trials Actually Test

Many people picture a single scenario: one group receives an experimental pill, another gets a sugar tablet. That model captures only a slice of the landscape. Modern trials examine combinations of existing drugs, evaluate medical devices, assess preventive interventions such as vaccines, test lifestyle modifications, and probe new methods for screening or diagnosing disease. For patients facing aggressive or terminal illnesses, enrollment can represent the single best available chance at extending life or preserving function.

“Cancer is often a fatal disease, and clinical trials offer an opportunity to try something that may or may not be better. If you know the existing standard of care has an average survival of eight months, you want something with a better opportunity.”

Mark Fleury, policy principal for emerging science at the American Cancer Society Cancer Action Network, makes the point that the stakes are rarely abstract. Patient advocates also emphasize a less-discussed benefit: even participants assigned to the control arm receive intensive monitoring and the gold standard of care — a level of surveillance many would not access outside a research protocol.

Washington Moves to Lower the Barriers

The urgency of improving participation has moved from advocacy back-rooms into legislative and executive action. In June, the Department of Health and Human Services launched an initiative aimed at streamlining and strengthening clinical research domestically. Among its components was a public request for information exploring whether federal rules that currently discourage sponsors from reimbursing participants for travel and lodging should be revised.

Then, in July, a coalition of nearly 200 patient-advocacy and public-health organizations delivered a joint letter to the Senate sponsors of the Clinical Trial Modernization Act, pressing for its passage. The proposed legislation would permit sponsors to cover participants’ medical out-of-pocket costs — insurance deductibles, copayments — as well as nonmedical expenses such as transportation and childcare. It would also shield up to $2,000 in trial-related financial support from federal taxation, preventing enrollment from jeopardizing eligibility for Medicaid or other income-based assistance programs. For low-income patients, that tax exclusion could be the difference between saying yes and saying no.

A Personal Stake in the Science

Not every participant enrolls hoping for a cure. Some join to contribute data that will help future patients. Jim Taylor’s wife, Geri, was diagnosed with Alzheimer’s disease in 2012 and died two years ago, more than a decade after that first diagnosis. The couple turned their grief into advocacy, and Taylor continues that work today. He is currently enrolled in three observational Alzheimer’s studies that employ cognitive testing and brain imaging to chart how his own cognition is shifting relative to cohorts already diagnosed with the disease.

“The reason I’ve done it is so I can explain to people, with some authenticness and experience, what a trial is like.”

Taylor’s participation illustrates a dimension of trial value that is easy to overlook: the lived testimony of someone who has walked through the protocol, sat in the scanner, and answered the questionnaires. That testimony carries a weight no brochure or website can replicate, and it helps close the trust gap that keeps so many eligible patients from ever walking through the door.

What a Patient Can Do Right Now

While federal rulemaking and congressional action proceed at their own pace, individuals who want to explore enrollment have practical steps available today. Asking a treating physician directly whether any trial matches their diagnosis is the simplest first move. National registries and patient-advocacy organizations maintain searchable databases that filter studies by condition, location, and phase. Understanding the specific costs a trial would impose — travel, time off work, copays — before signing a consent form allows a patient to negotiate logistics early rather than discover them mid-study. And for those who qualify for income-based assistance, confirming with a social worker that trial compensation will not disrupt benefits is a prudent step before committing.

The science that will define the next decade of medicine is already being written in protocols across the country. The bottleneck is no longer the absence of promising therapies; it is the friction between a willing patient and a system that has, until recently, done little to remove the practical barriers standing between them.